To explore how peptides are studied and applied across research settings, visit our Research Library.
Weight loss peptide research has a new benchmark — and the findings go well beyond the scale.
In December 2025, Eli Lilly announced positive Phase 3 results from the TRIUMPH-4 clinical trial evaluating retatrutide in adults with obesity and knee osteoarthritis. The trial tested two doses — 9 mg and 12 mg weekly — and the results were striking on both primary endpoints.
Participants at the highest dose achieved an average weight loss of approximately 71.2 pounds over the course of the study. That alone would make retatrutide one of the most effective weight loss compounds ever studied. But the headline buried in the press release may matter more long-term: participants also reported substantial relief from osteoarthritis pain and measurable improvement in physical function.
That second finding is significant because it suggests retatrutide’s effects aren’t purely driven by weight reduction offloading stress from joints. Researchers are investigating whether the compound’s glucagon receptor activity, the third target in its GIP/GLP-1/glucagon triple agonist mechanism, may be driving additional anti-inflammatory effects independent of weight loss itself. Retatrutide’s multi-receptor activity is part of a broader shift in metabolic research outlined in our Retatrutide Research Overview.
Retatrutide is a first-in-class once-weekly injectable that simultaneously activates receptors for GIP, GLP-1, and glucagon, a triple agonist approach that no approved drug currently uses. Earlier Phase 2 data had already positioned it as the highest-performing weight loss compound in clinical development, with reported reductions exceeding 28% of body weight. TRIUMPH-4 is the first Phase 3 confirmation of those results in a specific patient population. Earlier compounds such as Semaglutide and Tirzepatide helped establish the foundation for this new generation of metabolic therapies.
Seven additional Phase 3 trials evaluating retatrutide are expected to complete in 2026, covering type 2 diabetes, obstructive sleep apnea, chronic low back pain, cardiovascular outcomes, kidney disease, and metabolic liver disease. The full dataset emerging from the TRIUMPH program this year will be the most comprehensive look yet at what a triple agonist can do across multiple organ systems.
For the research community, the TRIUMPH-4 results raise a question that will drive the next wave of studies: how much of retatrutide’s benefit comes from weight loss, and how much comes from direct receptor-mediated effects on inflammation and tissue function? The answer could reshape how researchers think about the entire incretin class.
Retatrutide TRIUMPH-4 Phase 3 Trial Results — Eli Lilly and Company, December 2025
Peptides in Clinical Trials 2026: What Is Coming Next — Peptide Protocol Wiki, 2026